Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Boston Scientific (NYSE:BSX) reported fiscal Q4 2024 results that surpassed analyst expectations. The company's shares swung between gains and losses in premarket trading Wednesday. The company ...

Explore the debate on climate change causes: human activities vs. natural variability. Discover the latest data, scientific ...

Several Kentucky bills filed this legislative session have one thing in common: a shared skepticism of guidance from top U.S.

Boston Scientific (BSX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.55 per share a year ago. These ...

Trump's pick to run the Department of Health and Human Services gave away the agenda -- and may have invited a strong legal ...

Kennedy has suggested, contrary to scientific consensus, that certain vaccines are connected to childhood autism, asthma and ...

Underpinning the 269-page document are a number of statements — that doctors argue go against medical and scientific consensus — criticizing the use of vaccines and a range of other pandemic ...

The man who hopes to be President Donald Trump’s health secretary says he needs to see data showing vaccines are safe, but he ...

ChatGPT-4 was most accurate and had highest quality among three LLMs in answering rheumatology questions, but more than 70% of incorrect answers by all three had the potential to cause harm.

For fiscal year 2027, Eurofins reiterated an average of 6.5% organic growth and confirmed a 24% EBITDA margin target, although it has abandoned its €10 billion revenue goal and now expects further ...